COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency

Inclusion Criteria: * Patients aged 18 and over * Patient sex - male and female * Bone marrow transplant from a donor (sibling or unrelated) or after cell therapy (CART) at least 3 months before vaccination. * Patients with primary immunodeficiency syndrome. * Patients who are able to sign an informed consent form Exclusion Criteria: * Patients under 18 years of age * Patients who are unable to give informed consent * Patients with acute GVHD who require steroid therapy above 0.5 mg / kg or who have been diagnosed in the last month. * Patients with chronic GVHD who require steroid therapy above 0.5 mg / kg * Patients treated with rituximab / immunoglobulins / mesenchymal cells during the last month. * Patients whose disease is not completely cured and receive dedicated treatment for the disease. * Patients receiving maintenance treatment for the underlying disease (excluding TKIs such as sorfenib, midostaurin, guiltritinib or cranolinib). * Patients who have previously had COVID19. * Patients with severe allergy to one of the vaccine components.